about
The role of pembrolizumab in the treatment of advanced non-small cell lung cancerOvercoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationReal-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies.Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program.Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer.Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer.Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma: a Phase II multicenter study.Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerThe role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.Biological prognostic and predictive factors in lung cancer.Pemetrexed in advanced non-small cell lung cancer.Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.Individualized chemotherapy for elderly patients with nonsmall cell lung cancer.Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.Vinorelbine in the treatment of non-small cell lung cancer.Multidisciplinary treatment of malignant pleural mesothelioma.New targeted therapies and small-cell lung cancer.Oral cytotoxic drugs.Pemetrexed in the treatment of advanced non-squamous lung cancer.Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?Chemotherapy of non-small cell lung cancer in the elderly.Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.CD40 activation as potential tool in malignant neoplasms.Treating advanced non-small cell lung cancer in the elderly.5-HT3-receptor antagonists in the control of delayed-onset emesis.Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents.Treatment of advanced non small cell lung cancer.Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients.The role of targeted therapy in non-small cell lung cancer.Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics.Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.Screening for lung cancer: New horizons?
P50
Q26744076-70394700-7E96-4AA5-8BDF-AE5A23113FDEQ26795556-2A987731-EC74-4691-90F7-703E395AF219Q30234800-84F352F1-C060-4629-ABE8-F510F720587DQ30947183-AA595C7B-422B-4C5F-BC4D-03FFEFC22D0CQ31108477-94A4CF4A-7E31-406E-808A-E4255A982009Q33341178-5D7DEAAF-8522-4339-8B45-59B1E1B13483Q33343371-4921D032-93B2-49D3-85CA-A3ED8A071F95Q33348642-3CDFAE00-ABC1-4733-BC4B-842B325C8778Q33357111-9D698AA5-6C9C-4128-AD9F-08C37638F012Q33374797-D06A26F2-0A4D-4ECD-8AA2-9C04D11837C1Q33379422-3B4B2BDC-DB2F-4C81-8C41-ACA71E8107BCQ33521596-48EA28CD-448D-4A61-9E97-D1A195FCA382Q33890538-1A3FCBAA-418B-4608-8D1C-43822D6447A0Q34041708-04D64931-ADBE-4F41-8D63-6A942FC7107AQ34091239-CF1B1DF3-E09C-4D66-9BC4-D737E6D16580Q34096776-134E2FBA-1A02-4322-AAFD-A37E5799AC54Q34160513-EF51C125-98D2-4805-9502-F9D1D7C22B4FQ34219342-C68C17AD-6D71-4471-8D0C-F7558A2C6ABCQ34553204-79545DD7-6DC5-4973-A1E4-960EAAC7B436Q34579641-2A3E5DBE-AE60-460E-B1FB-CF65A8C5943CQ34608375-A50F86BF-0362-44E4-81CA-4CC227D650EFQ34609266-2D7277E4-D8CD-43F8-84C7-11A887912FA5Q34659099-729E5A2E-F711-437F-AFEB-C2AF6B8E3A03Q34840415-D712667C-13D6-4B12-AD37-65F2282175F8Q34988769-A0B940B9-8472-42AB-B016-0E184F2FB8A4Q34990679-2C8BBEC2-7C6C-4108-BB85-4032D599E449Q34997106-66A45AE9-7BA2-45C3-BC53-728D18BC4E3CQ35017988-F1ECE032-116B-4201-AF0D-B95EF03FDBAEQ35024740-22EF60BF-9F3D-4B95-9D61-C030B2F629B6Q35028360-D92E610B-3951-48FA-BE93-07F4B66B6E16Q35076283-32C17377-D784-4481-9A2C-F2A0058A501BQ35202565-EB9BA274-D79E-4496-9E4C-7DBC49603339Q35551162-E0D49176-D2A4-4EDD-86DA-F5F9142F6F89Q35667817-F14C5237-3201-42C3-A0F5-2836907168FCQ35681839-C921D6F2-DADB-4E92-88E0-B74B19E6A25DQ35810720-A792F360-1C9E-4BC0-A43F-326E63B11CB8Q35896202-DA6C704E-A449-412F-8203-C7D038A27222Q35922752-8E3D1AE2-AAC5-4A6B-9BB7-41282562E328Q36110382-AA8620FA-DC1F-42DD-8A5E-874B856E1856Q36175012-3B3801E3-9F7E-437D-BC25-B42FE5D6D3C1
P50
name
Cesare Gridelli
@en
Cesare Gridelli
@nl
type
label
Cesare Gridelli
@en
Cesare Gridelli
@nl
prefLabel
Cesare Gridelli
@en
Cesare Gridelli
@nl